Thread by @AbraarKaran

1/
mRNA1273 (Moderna) vaccine- Phase 3 trial

2 doses, 28 days apart (black arrows)

28,207 in per-protocol analysis

Primary end-point: preventing symptomatic infections w/ onset at least 14 days after 2nd dose

Overall: 94.1% vaccine efficacy

nejm.org/doi/full/10.10…

2/ Key secondary end-point: preventing severe #Covid19 disease

Vaccine group- 0 severe cases

Placebo group- 30 severe cases

Vaccine efficacy of 100% in preventing severe disease

3/ "In addition, although our trial showed that mRNA-1273 reduces the incidence of symptomatic SARS-CoV-2 infection, the data were not sufficient to assess asymptomatic infection" (cont)

#covid19

4/ "although our results from a preliminary exploratory analysis suggest that some degree of prevention may be afforded after the first dose."

Important points here-- interested to see results from this analysis.

#covid19

5/ "Pregnant women and children were excluded from this trial, and additional evaluation of the vaccine in these groups is planned."

6/ Accompanying editorial brings up key points
"How long neutralizing antibodies will last is not known, although follow-up studies in the phase 1 mRNA-1273 trial demonstrated persistence of neutralizing antibodies 3 months after the 2nd dose of vaccine"

nejm.org/doi/full/10.10…

7/ "...analysis of virus escape from protective immune responses and long-term follow-up for rare safety events are needed"

The only part of the editorial that I disagree w/
"Our only hope is safe and effective vaccines..."; that's not true, but they are critical.

#covid19